Figure legends
Figure 1. Flow diagram of advanced NSCLC patients enrolled in the study (n = 232). NSCLC, non–small cell lung cancer.
Figure 2. Histogram showing the number of concomitant medications and prevalence in older advanced NSCLC patients (n = 232). NSCLC, non–small cell lung cancer.
Figure 3. Survival analysis of PP(+) and PP(–) older advanced NSCLC patients. Estimated Kaplan–Meier survival curves for (A)PFS and (B) OS for PP(+) patients (n = 89) and PP(−) patients (n = 143). NSCLC, non–small cell lung cancer; PP, polypharmacy; PFS, progression-free survival; OS, overall survival.
Figure 4. (A) Comparison of number of concomitant medications among older advanced NSCLC patients classified by clinical factors. *P < 0.05. (B) Cluster analysis dendrogram showing the correlation of CCI scores with the number of concomitant medications. NSCLC, non–small cell lung cancer; M factor, number of organs involved in metastasis; ECOG-PS, Eastern Cooperative Oncology Group–Performance Status; GRIm, Gustave Roussy Immune Score; Total, total number of concomitant medications; CCI, Charlson Comorbidities Index.